Alzheimer's disease trials recruiting in Michigan

All Alzheimer's disease trials nationally

Cities in Michigan

Recruiting trials in Michigan

• A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
  NCT07170150 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female) · Michigan: Farmington Hills
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
  NCT07011745 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · Michigan: Ann Arbor
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
  NCT07011732 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · Michigan: Bloomfield Hills, Troy
• A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
  NCT07602582 · Phase: Phase 3 · Ages: 55 Years and older · Sex: All (male and female) · Michigan: Southfield
• A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
  NCT07589595 · Phase: Phase 2 · Ages: 55 Years to 85 Years · Sex: All (male and female) · Michigan: Farmington Hills
• A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
  NCT06657768 · Phase: Phase 1 · Ages: 45 Years to 85 Years · Sex: All (male and female) · Michigan: Farmington Hills
• A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
  NCT07633470 · Phase: Phase 4 · Ages: 50 Years and older · Sex: All (male and female) · Michigan: Farmington Hills
• A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
  NCT06126224 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · Michigan: Rochester Hills
• A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
  NCT06585787 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · Michigan: Bloomfield Township
• A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
  NCT06976203 · Phase: Phase 3 · Ages: 60 Years to 85 Years · Sex: All (male and female) · Michigan: Farmington Hills
• A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
  NCT06937229 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · Michigan: Troy
• ACP-204 in Adults With Alzheimer's Disease Psychosis
  NCT06159673 · Phase: Phase 2, Phase 3 · Ages: 55 Years to 95 Years · Sex: All (male and female) · Michigan: Rochester Hills
• Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
  NCT06563895 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Michigan: Detroit
• Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
  NCT06584357 · Phase: Not specified · Ages: 60 Years to 90 Years · Sex: All (male and female) · Michigan: Farmington Hills
• Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device
  NCT07701161 · Phase: Not specified · Ages: 40 Years to 90 Years · Sex: All (male and female) · Michigan: Dearborn, Flint, Owosso
• Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders
  NCT05929703 · Phase: Not applicable (e.g. observational or device study) · Ages: 70 Years and older · Sex: All (male and female) · Michigan: Ann Arbor
• Michigan Healthy Mom (MI-MOM) Pregnancy Improvement Web Application Trial
  NCT07213284 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female · Michigan: Corunna, Flint, Gaylord, Grand Rapids
• Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
  NCT05980949 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · Michigan: Bloomfield Township, Rochester Hills
• Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
  NCT07177352 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female) · Michigan: Farmington Hills
• Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
  NCT06808984 · Phase: Phase 2 · Ages: 55 Years to 90 Years · Sex: All (male and female) · Michigan: Sterling Heights